XTalks

JUNE 14, 2023

“The clinical trials consistently showed significant therapeutic improvements in ocular surface damage and associated symptoms, while pioneering visual function improvement analysis”, said John D. Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

The Pharma Data

JULY 12, 2021

“It continues to be critically important to advance potential antiviral treatments to address the devastating impact of COVID-19 globally,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “If About Molnupiravir. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Clinical Trials Bioavailability Trials 52

The Pharma Data

MARCH 8, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. About Molnupiravir. About Ridgeback Biotherapeutics.

Trials 69

Trials In-Vivo Genotoxicity RNA 69